Across TCGA pan-cancer cohorts, STK38L mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated STK38L data layer compared with 23 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher STK38L mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated STK38L expression acts as an unfavorable survival marker, although some lineages such as PDAC and LSCC show a favorable association.

PDAC, LSCC, and LUAD are the cancer types where STK38L mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Quartile	II,III,IV	0.962	0.683	<.001	40	view →
LSCC	OS	Median	II,III,IV	0.936	0.730	.003	22	view →
LUAD	OS	Tertile	II,III,IV	0.445	1.000	.005	19	view →
GBM	OS	Quartile	All	0.207	0.618	.033	2	view →
HNSC	OS	Median	All	0.943	0.991	.031	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: STK38L tumor-vs-normal RNA expression · all STK38L data types